Future Direction for Orphan Drugs in Europe
|Event Date/Time: Nov 04, 2010||End Date/Time: Nov 04, 2010|
â€¢ Orphan Designation: What have we learned and what has changed in the course of the first 10 years?
â€¢ Marketing Authorisation for Orphan Drugs: Significant benefit, similarity, market exclusivity and other challenges
â€¢ Orphan Rewards and Incentives: What is the value of orphan designation?
â€¢ Market Access and HTA: Particular challenges and opportunities for orphan drugs